Back to results
US 11,993,816 B2Granted
Circulating microRNA as biomarkers for endometriosis
AssigneeYale University
InventorsHugh Taylor, SiHyun Cho
Life of this patent
Estimating the term…
Abstract
The invention includes compositions and methods useful for the diagnosis, assessment, and characterization of endometriosis in a subject in need thereof, based upon the expression level of at least one miRNA that is associated with endometriosis.
Claims51
A noninvasive method of detecting miRNA in a subject, the method comprising:
- (a) providing a biological sample comprising saliva from the subject, wherein the subject has endometriosis or is suspected of having endometriosis, and wherein the biological sample comprises at least one miRNA that is a biomarker for endometriosis, wherein at least one miRNA that is a biomarker for endometriosis comprises let-7b miRNA;
- and
- (b) performing an in vitro amplification procedure on the at least one miRNA that is a biomarker for endometriosis;
- and
- (c) detecting a level of the at least one miRNA that is a biomarker for endometriosis in the biological sample comprising saliva from the subject;
- and
- (d) treating the subject for endometriosis based on the detected level of the at least one miRNA that is a biomarker for endometriosis in the biological sample comprising saliva from the subject, wherein the treating the subject comprises administering a hormonal treatment, an oral contraceptive, a progestin, a GnRH agonist, an androgen, an aromatase inhibitor, a non-steroidal anti-inflammatory drug, or a combination thereof, wherein the detected level of the let-7b miRNA is downregulated, and wherein the downregulation is statistically significant.
4 more elements
A noninvasive method of detecting endometriosis in a subject, the method comprising detecting in a biological sample obtained from a body fluid altered expression of at least one miRNA selected from the group consisting of let-7a, let-7b, and let-7d, in a subject suspected of or having endometriosis;
- and treating the subject for endometriosis based on the detected level of the at least one miRNA in the subject, wherein the treating the subject comprises administering a hormonal treatment, an oral contraceptive, a progestin, a GnRH agonist, an androgen, an aromatase inhibitor, a non-steroidal anti-inflammatory drug, or a combination thereof, wherein the detected level of let-7a, let-7b, or let-7d is downregulated, and wherein the downregulation is statistically significant.
Dependencies are inferred from the claim text.